Clinical Trial Update: A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 [Phase 3]

View source ↗

Summary

Phase 3 trial comparing IPX066 to carbidopa/levodopa/entacapone (CLE) with an open-label safety study of IPX066 completed; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Carbidopa/levodopa/entacapone (carbidopa; levodopa; entacapone)
• IPX066 (carbidopa-levodopa formulation)

Snippet

Sponsor: Impax Laboratories, LLC | Conditions: Parkinson's Disease | Phase 3 | Status: COMPLETED | Results posted: 2017-09-13